Skip to main content
Top
Published in: Molecular Imaging and Biology 3/2015

01-06-2015 | Brief Article

SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors

Authors: C. Kratochwil, M. Stefanova, E. Mavriopoulou, T. Holland-Letz, A. Dimitrakopoulou-Strauss, A. Afshar-Oromieh, W. Mier, U. Haberkorn, F. L. Giesel

Published in: Molecular Imaging and Biology | Issue 3/2015

Login to get access

Abstract

Purpose

The goal of our study was to quantify the expression of the somatostatin receptors (SSTR2) using the maximum standardized uptake value (SUVmax) of [68Ga]DOTA(0)-Phe(1)-Tyr(3)-octreotide (DOTATOC) positron emission tomography (PET)-computed tomography (CT) in liver metastases of patients with neuroendocrine tumors (NETs) prior to peptide receptor radiation therapy (PRRT) and compare the initial tumor uptake with the final treatment outcome.

Procedures

SSTR2 expression of the 60 liver metastases in 30 NET patients was assessed at baseline and after PRRT by measuring SUVmax, tumor to spleen ratio (T/S ratio), and tumor to liver ratio (T/L ratio). Based on morphological changes and tumor size measured at baseline and follow-up contrast-enhanced CT (after three cycles of PRRT), lesions were divided into two groups by the following: (i) responding (n = 40) and (ii) non-responding (n = 20).

Results

Statistically significant differences were observed in the mean SUVmax for non-responding vs. responding lesions at baseline (18.00 ± 3.59 vs. 33.55 ± 4.62, p < 0.05) and for the mean T/S ratio (1.20 ± 0.37 vs. 1.90 ± 0.45, p < 0.05) and the mean T/L ratio (3.15 ± 0.53 vs. 4.97 ± 0.62, p < 0.05). Using the receiver operating characteristic curves, SUVmax was found a better metric than both T/L ratio and T/S ratio (area under the curve (AUC) of SUVmax 0.87; T/L ratio 0.78; T/S ratio 0.73) as a stratification criterion. Using a threshold value of >16.4 for SUVmax, the sensitivity and specificity in predicting responding lesions were 95 and 60 %, respectively.

Conclusion

We propose a SUVmax cutoff of >16.4 from [68Ga]DOTATOC-PET-CT to select patients for PRRT. A T/L ratio >2.2 might present a scanner-independent criterion that enables the translation of our results to other institutions. However, the robustness of this arbitrary unit still needs to be evaluated with different PET scanners.
Literature
1.
go back to reference Rinke A, Muller HH, Brittinger CS et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663CrossRefPubMed Rinke A, Muller HH, Brittinger CS et al (2009) Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 27:4656–4663CrossRefPubMed
2.
go back to reference Modlin IM, Oberg K, Chung DC et al (2008) Gastroeneteropancreatic neuroendocrine tumors. Lancet Oncol 9:61–72CrossRefPubMed Modlin IM, Oberg K, Chung DC et al (2008) Gastroeneteropancreatic neuroendocrine tumors. Lancet Oncol 9:61–72CrossRefPubMed
3.
go back to reference Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine tumors. Cancer 117:268–275CrossRefPubMed Strosberg JR, Fine RL, Choi J et al (2011) First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine tumors. Cancer 117:268–275CrossRefPubMed
5.
go back to reference Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513CrossRefPubMed Raymond E, Dahan L, Raoul JL et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 364:501–513CrossRefPubMed
6.
go back to reference Van Essen M, Krenning EP, De Jong M et al (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723–734CrossRefPubMed Van Essen M, Krenning EP, De Jong M et al (2007) Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46:723–734CrossRefPubMed
7.
go back to reference Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastropancreatic tumors. J Clin Oncol 23:2754–2762CrossRefPubMed Kwekkeboom DJ, Teunissen JJ, Bakker WH et al (2005) Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastropancreatic tumors. J Clin Oncol 23:2754–2762CrossRefPubMed
8.
go back to reference Gabriel M, Oberauer A, Dobroyemsky G et al (2009) 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin- receptor–mediated radionuclide therapy. J Nucl Med 50:1427–1434CrossRefPubMed Gabriel M, Oberauer A, Dobroyemsky G et al (2009) 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin- receptor–mediated radionuclide therapy. J Nucl Med 50:1427–1434CrossRefPubMed
9.
go back to reference Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52CrossRefPubMed Miederer M, Seidl S, Buck A et al (2009) Correlation of immunohistopathological expression of somatostatin receptor 2 with standardised uptake values in 68Ga-DOTATOC PET/CT. Eur J Nucl Med Mol Imaging 36:48–52CrossRefPubMed
10.
go back to reference Оtte A, Mueller-Brand J, Dellas S et al (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–418CrossRef Оtte A, Mueller-Brand J, Dellas S et al (1998) Yttrium-90-labelled somatostatin-analogue for cancer treatment. Lancet 351:417–418CrossRef
11.
go back to reference Giesel FL, Kratochwil C, Mehndiratta A et al (2012) Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 81:2820–2825CrossRefPubMed Giesel FL, Kratochwil C, Mehndiratta A et al (2012) Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur J Radiol 81:2820–2825CrossRefPubMed
12.
go back to reference Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130CrossRefPubMed Kwekkeboom DJ, de Herder WW, Kam BL et al (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3] octreotate: toxicity, efficacy, and survival. J Clin Oncol 26:2124–2130CrossRefPubMed
13.
go back to reference Campana D, Ambrosini V, Pezzilli R et al (2010) Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 51:353–359CrossRefPubMed Campana D, Ambrosini V, Pezzilli R et al (2010) Standardized uptake values of 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J Nucl Med 51:353–359CrossRefPubMed
14.
go back to reference Koukouraki S, Strauss LG, Georgoulias V et al (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466CrossRefPubMed Koukouraki S, Strauss LG, Georgoulias V et al (2006) Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33:460–466CrossRefPubMed
15.
go back to reference Pfeifer AK, Gregersen T, Grønbæk H et al (2011) Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93:189–196CrossRefPubMed Pfeifer AK, Gregersen T, Grønbæk H et al (2011) Peptide receptor radionuclide therapy with Y-DOTATOC and (177)Lu-DOTATOC in advanced neuroendocrine tumors: results from a Danish cohort treated in Switzerland. Neuroendocrinology 93:189–196CrossRefPubMed
16.
go back to reference Haug A, Auernhammer CJ, Wängler B (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770CrossRefPubMed Haug A, Auernhammer CJ, Wängler B (2009) Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 36:765–770CrossRefPubMed
Metadata
Title
SUV of [68Ga]DOTATOC-PET/CT Predicts Response Probability of PRRT in Neuroendocrine Tumors
Authors
C. Kratochwil
M. Stefanova
E. Mavriopoulou
T. Holland-Letz
A. Dimitrakopoulou-Strauss
A. Afshar-Oromieh
W. Mier
U. Haberkorn
F. L. Giesel
Publication date
01-06-2015
Publisher
Springer US
Published in
Molecular Imaging and Biology / Issue 3/2015
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-014-0795-3

Other articles of this Issue 3/2015

Molecular Imaging and Biology 3/2015 Go to the issue